Join
Live feed
·
INSIDERFilingvia Quantisnow
Ultragenyx Pharmaceutical Inc. logo

Director Fust Matthew K was granted 5,740 shares, increasing direct ownership by 28% to 25,945 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
RARE· Ultragenyx Pharmaceutical Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RARE (Ultragenyx Pharmaceutical Inc.) and more on Quantisnow.